Back to News
IQ DILI Collaborates with DILI Experts to Develop Guidelines Featured in AP&T
December 6, 2019
The IQ Consortium Drug Induced Liver Injury Initiative (IQ DILI) collaborated with DILI experts from across academia, industry and US FDA to develop comprehensive guidelines addressing best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Their findings, featured in Alimentary Pharmacology & Therapeutics, are based on extensive literature review and discussions between numerous drug safety & DILI subject matter experts to achieve consensus on common questions related to this crucial topic.